934426-22-9

Basic information

• Product Name: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
• Synonyms: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
• CAS NO: 934426-22-9
• Molecular Formula: C₁₃H₁₇BN₂O₂
• Molecular Weight: 244.09728
• Mol File: 934426-22-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(934426-22-9)
• EPA Substance Registry System: 2-aMino-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(934426-22-9)

Safety Data

• Hazardous Substances Data: 934426-22-9(Hazardous Substances Data)

Usage

Common usage

Building block in organic synthesis and medicinal chemistry

Derivative

Derived from benzonitrile

Structural feature

Contains a boron atom linked to a tetramethyl-dioxaborolane group

Potential applications

Pharmaceuticals and agrochemicals development
Preparation of fluorescent dyes
Materials for organic electronic devices
Catalysis
Reagent in organic reactions

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 1885-29-6 anthranilic acid nitrile 
• 5922-60-1 2-amino-5-chlorobenzonitrile 
• 39263-32-6 2-amino-5-bromobenzonitrile 
• 132131-24-9 5-iodoanthranilonitrile 

Downstream Products

• 934426-24-1 N'-[2-cyano-4-(4,4,5,5-tetramethyl-[1.3.2]dioxaborolan-2-yl)-phenyl]-N,N-dimethyl-formamidine 
• 1292317-50-0 2-amino-5-(2-chloropyrimidin-4-yl)benzonitrile 
• 1443283-34-8 2-amino-5-[1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-46-2 2-amino-5-[2-methyl-3-phenyl-4-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-73-5 2-amino-5-[1-methyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-71-3 2-amino-5-[2-methyl-4-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-51-9 2-amino-5-[4-(difluoromethyl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1279842-22-6 2-amino-5-[4-(difluoromethyl)-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443284-00-1 2-amino-5-[4-(difluoromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-55-3 2-amino-5-[4-(difluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443284-09-0 2-amino-5-[4-(difluoromethyl)-3-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-77-9 2-amino-5-[4-(difluoromethyl)-3-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 
• 1443283-66-6 2-amino-5-(4-(difluoromethyl)-1-(2-(dimethylamino)ethyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile 
• 1443283-81-5 2-amino-5-[4-(difluoromethyl)-3-(3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile 

Relevant articles and documents

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF

The present invention aims to provide a compound that: has an excellent cytotoxic action on cancer cells, excellent induction of BET protein degradation in cancer cells, and an excellent binding-inhibiting action on BET protein and acetylated histone; and is effective as an anti-cancer agent, a BET protein degradation-inducing agent, or a BET protein inhibiting agent. A compound indicated in general formula (I) or a pharmacologically acceptable salt thereof. {In the formula, each symbol is as outlined in the Description.}

Para-Selective C-H Borylation of Common Arene Building Blocks Enabled by Ion-Pairing with a Bulky Countercation

The selective functionalization of C-H bonds at the arene para position is highly challenging using transition metal catalysis. Iridium-catalyzed borylation has emerged as a leading technique for arene functionalization, but there are only a handful of strategies for para-selective borylation, which operate on specific substrate classes and use bespoke ligands or catalysts. We describe a remarkably general protocol which results in para-selectivity on some of the most common arene building blocks (anilines, benzylamines, phenols, benzyl alcohols) and uses standard borylation ligands. Our strategy hinges upon the facile conversion of the substrates into sulfate or sulfamate salts, wherein the anionic arene component is paired with a tetrabutylammonium cation. We hypothesize that the bulk of this cation disfavors meta-C-H borylation, thereby promoting the challenging para-selective reaction.

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors

Pim kinases are promising therapeutic targets for the treatment of hematological cancers. A potent Pim kinase inhibitor 7f, derived from meridianin C, was further optimized by the replacement of 2-aminopyrimidine with substituted benzene. The optimization of the C-3 and C-5 positions of indole yielded compound 43 with improved cellular potency and high selectivity against a panel of 14 different kinases.

Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation

Human African trypanosomiasis (HAT) is a deadly disease in need of new chemotherapeutics that can cross into the central nervous system. We previously reported the discovery of 2 (NEU-617), a small molecule with activity against T. brucei bloodstream prol

TANK-BINDING KINASE INHIBITOR COMPOUNDS

Compounds having the following formula (I) and methods of their use and preparation are disclosed:

TANK-BINDING KINASE INHIBITOR COMPOUNDS

Compounds having the following formula (I) and methods of their use and preparation are disclosed:

PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER

The invention relates to the use of compounds corresponding to formula (I), or a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer.